Scpharmaceuticals INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
Weiss Asset Management LP, WAM GP LLC, and Andrew M. Weiss report zero beneficial ownership in scPharmaceuticals Inc. common stock.
Laurence W. Lytton has filed an amendment to Schedule 13G, reporting zero beneficial ownership of scPharmaceuticals Inc. common stock.
Weiss Asset Management LP, along with WAM GP LLC and Andrew M. Weiss, has reported a 5.4% beneficial ownership stake in scPharmaceuticals Inc. common stock.
AIGH Capital Management LLC and Orin Hirschman have reported a complete divestment of their beneficial ownership in SCPHARMACEUTICALS INC., now holding 0% of common stock.
Tudor Investment Corporation and Paul T. Jones II have reported divesting their beneficial ownership in scPharmaceuticals Inc., reducing their stake to 0%.
Luther King Capital Management Corporation and J. Luther King, Jr. reported a 4.0% beneficial ownership in scPharmaceuticals Inc., holding 2,128,391 shares as of September 30, 2025.
Glazer Capital, LLC and Paul J. Glazer report a beneficial ownership of 4.64% in scPharmaceuticals Inc., indicating a reduction below the 5% threshold.
SCHEDULE: Luther King Capital Management and J. Luther King Jr. Increase Stake in scPharmaceuticals to Over 6%
Luther King Capital Management Corporation and J. Luther King, Jr. have reported increased beneficial ownership in scPharmaceuticals Inc., holding 6.7% and 7.0% of common stock respectively, as of June 30, 2025.
SCHEDULE 13G/A: Luther King Capital Management and J. Luther King Jr. Disclose Significant Stake in scPharmaceuticals Inc.
Luther King Capital Management Corporation and J. Luther King, Jr. have filed an amended Schedule 13G, disclosing their beneficial ownership of scPharmaceuticals Inc. common stock as of March 31, 2025.
SCHEDULE 13G/A: AIGH Capital Management and Orin Hirschman Disclose Significant Passive Stake in SCPHARMACEUTICALS INC.
AIGH Capital Management LLC and Orin Hirschman have jointly disclosed beneficial ownership of 8.4% and 8.3% respectively, of SCPHARMACEUTICALS INC.'s common stock as of December 31, 2024, held for ordinary course investment purposes.
SCHEDULE 13G/A: Luther King Capital Management and J. Luther King Jr. Disclose Significant Stakes in scPharmaceuticals Inc.
Luther King Capital Management Corporation and J. Luther King Jr. have filed an amended Schedule 13G, disclosing beneficial ownership of 5.7% and 6.0% respectively, in scPharmaceuticals Inc. common stock as of December 31, 2024.